CII
WX

CR Intrinsic Investors’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

CR Intrinsic Investors’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-50,000
Closed -$1.37M – 434
2013
Q3 		$1.37M Hold
50,000
– – 0.04% 311
2013
Q2 		$1.05M Buy
+50,000
New +$976K 0.04% 307

Other funds holding WX

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
CI Investments Inc
CI Investments Inc Toronto, Ontario, Canada $20.6B AUM 29.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CR Intrinsic Investors's WX Position: Q4 2013 in Review

CR Intrinsic Investors sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2013, closing a stake of 50,000 shares — an estimated $1.37M sold.

CR Intrinsic Investors first reported a position in WX in Q2 2013 and held it in 2 quarters. The position peaked at $1.37M in Q3 2013. 164 funds tracked by Wall St. Rank hold WX as of Q4 2013.

  • CR Intrinsic Investors reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 50,000 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2013, an estimated $1.37M.
  • CR Intrinsic Investors first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 2 quarters.
  • CR Intrinsic Investors's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $1.37M in Q3 2013.
  • 164 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.